As of 2025-03-17, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -13.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 7,789.93 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -567.16 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 15.3x | 13.6x |
| Forward P/E multiples | 15.3x - 16.2x | 15.6x |
| Fair Price | (53.49) - (53.61) | (51.53) |
| Upside | -262.3% - -262.6% | -256.3% |
| Date | EV/EBITDA |
| 2025-03-14 | -13.74 |
| 2025-03-13 | -13.51 |
| 2025-03-12 | -13.61 |
| 2025-03-11 | -13.52 |
| 2025-03-10 | -13.21 |
| 2025-03-07 | -13.27 |
| 2025-03-06 | -13.49 |
| 2025-03-05 | -14.41 |
| 2025-03-04 | -13.93 |
| 2025-03-03 | -13.75 |
| 2025-02-28 | -14.38 |
| 2025-02-27 | -14.16 |
| 2025-02-26 | -13.90 |
| 2025-02-25 | -14.20 |
| 2025-02-24 | -14.83 |
| 2025-02-21 | -15.04 |
| 2025-02-20 | -15.02 |
| 2025-02-19 | -14.85 |
| 2025-02-18 | -14.58 |
| 2025-02-14 | -14.38 |
| 2025-02-13 | -13.26 |
| 2025-02-12 | -13.39 |
| 2025-02-11 | -13.11 |
| 2025-02-10 | -13.33 |
| 2025-02-07 | -13.36 |
| 2025-02-06 | -13.64 |
| 2025-02-05 | -13.93 |
| 2025-02-04 | -13.74 |
| 2025-02-03 | -13.08 |
| 2025-01-31 | -14.15 |
| 2025-01-30 | -14.74 |
| 2025-01-29 | -14.91 |
| 2025-01-28 | -14.86 |
| 2025-01-27 | -14.98 |
| 2025-01-24 | -15.28 |
| 2025-01-23 | -15.12 |
| 2025-01-22 | -14.70 |
| 2025-01-21 | -14.78 |
| 2025-01-17 | -14.01 |
| 2025-01-16 | -14.12 |
| 2025-01-15 | -14.42 |
| 2025-01-14 | -14.62 |
| 2025-01-13 | -13.99 |
| 2025-01-10 | -12.43 |
| 2025-01-08 | -12.55 |
| 2025-01-07 | -12.35 |
| 2025-01-06 | -12.16 |
| 2025-01-03 | -12.11 |
| 2025-01-02 | -12.14 |
| 2024-12-31 | -11.88 |